Janssen (Italy)

Recent papers from Janssen (Italy)

1. The efficacy and safety of macitentan in Fontan-palliated patients: results of the 52-week randomised, placebo-controlled RUBATO trialEuropean Heart Journal · 2022
2. Maltogenic amylase as a clean-label strategy to improve gluten-free bread quality and stability, with potential implications for bread waste reductionDiscover Food · 2026
3. Childhood trauma and treatment compliance in people with multiple sclerosis: The mediating role of physician–patient rapportMultiple Sclerosis and Related Disorders · 2026
4. Spontaneous orienting of untrained companion dogs naïve to human epilepsy toward odor samples from an unfamiliar human in a controlled non-social paradigm: a proof-of-concept.2026
5. Challenges in data-driven catalysis modelling: case study on palladium-NHC catalyzed Suzuki–Miyaura reactionsChemical Science · 2026
6. Decentralised Identity and PUF-Based Zero-Knowledge Proofs for IoUT Applications2025
7. Real‐World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic LandscapeJournal of the Peripheral Nervous System · 2025
8. Guselkumab and Il-17 Inhibitors Improve Patient-Perceived Impact of Psoriatic Arthritis Similarly: 6 Month Interim Results of the PsABIOnd Observational Cohort StudyThe Journal of Rheumatology · 2025
9. Unveiling the impact of ligand configurations and structural fluxionality on virtual screening of transition-metal complexesDigital Discovery · 2025
10. Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trialENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2024
11. Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertensionCPT Pharmacometrics & Systems Pharmacology · 2024
12. Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in EuropePatient Preference and Adherence · 2024
13. Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weightingJournal of Comparative Effectiveness Research · 2024
14. Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical TrialDermatology and Therapy · 2024
15. Efficacy and safety of macitentan in Fontan-palliated patients: 52-week randomized, placebo-controlled RUBATO phase 3 trial and open-label extensionJournal of Thoracic and Cardiovascular Surgery · 2024
16. Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study)Advances in Therapy · 2024
17. Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH‐CTD): Real‐world experience from EXPOSUREPulmonary Circulation · 2024
18. Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER studyJournal of the European Academy of Dermatology and Venereology · 2024
19. OPT-In; Optimized Patient Treatment Outcomes in Plaque Psoriasis: A 3-Year State-Transition Treatment-Sequencing Model in the Italian SettingDermatology and Therapy · 2024
20. L2086F Mutant ROS1-Rearranged NSCLC Resistant to Repotrectinib Responds to Cabozantinib: A Case ReportJTO Clinical and Research Reports · 2024